Rheumatoid arthritis cases growing by 1% annually
Drugs in the rheumatoid arthritis (RA) space are among the world’s biggest sellers, something that is not likely to change given the increasing prevalence of this condition.
A report from GlobalData states that diagnosed prevalent cases in the eight major markets (8MM) are expected to increase from 4.6 million in 2019 to 5.1 million in 2029, at an annual growth rate (AGR) of 1.06%.
The report, Rheumatoid Arthritis – Epidemiology Forecast to 2029, reveals that the USA is expected to have the highest number of diagnosed prevalent cases with around 1.6 million, followed by Japan with 1.1 million. Australia, with the lowest, will have an estimated 97,000.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze